首页> 外文期刊>Annals of Tropical Paediatrics: International Child Health >Comparative study of the effectiveness and pharmacokinetics of two rectal artesunate/oral mefloquine combination regimens for the treatment of uncomplicated childhood falciparum malaria
【24h】

Comparative study of the effectiveness and pharmacokinetics of two rectal artesunate/oral mefloquine combination regimens for the treatment of uncomplicated childhood falciparum malaria

机译:两种青蒿琥酯/口服甲氟喹联合用药方案治疗儿童单纯性恶性疟疾的有效性和药代动力学的比较研究

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Rectal artesunate has been shown to be an effective treatment for falciparum malaria and is useful in patients who cannot take medicine orally or when parenteral medication is inconvenient. A combination with mefloquine can decrease the duration of treatment, increase compliance and delay development of resistance. There are no clear data on whether a higher dosage of rectal artesunate results in a better clinical response.Aim: To assess two rectal artesunate/oral mefloquine regimens for treating uncomplicated multi-drug-resistant childhood falciparum malaria.Methods: Seventy children aged 1-14 years with uncomplicated falciparum malaria were randomly assigned to receive either 10 (range 8-12) or 20 (range 16-24) mg/kg/day rectal artesunate for 3 days followed by 25 mg/kg oral mefloquine. The study endpoints were fever clearance time, parasite clearance time and proportion of patients with recrudescence. Serum levels of artesunate and dihydro-artemisinin were measured after the first dose of rectal artesunate in 16 subjects.Results: Both regimens were safe and effective. The cure rate was 100% in the 53 patients who completed 28-day follow-up. All of the study endpoints were comparable between both treatment groups.Conclusion: A regimen of rectal artesunate 10 mg/kg/day for 3 days followed by mefloquine 25 mg/kg is optimal for the treatment of uncomplicated falciparum malaria. There was no definite benefit from increasing the dosage of rectal artesunate from 10 to 20 mg/kg/day.
机译:背景:青蒿琥酯已被证明是治疗恶性疟疾的有效方法,对不能口服药物或肠胃外药物不便的患者有用。与甲氟喹合用可减少治疗时间,增加依从性并延迟耐药性的发展。方法:70例1岁以下的儿童共70例1岁的儿童,尚无明确的数据表明高剂量的青蒿琥酯是否能带来更好的临床反应。目的:评估两种直肠青蒿琥酯/口服甲氟喹方案来治疗单纯性多药耐药的儿童恶性恶性疟疾。 14年无单纯性恶性疟疾的患者随机分配接受青蒿琥酯10毫克(范围8-12)或20毫克(范围16-24)/天,连续3天,然后口服25 mg / kg甲氟喹。研究终点为发烧清除时间,寄生虫清除时间和复发患者的比例。首次服用直肠青蒿琥酯后,对16名受试者进行了血清青蒿琥酯和二氢青蒿素的测定。结果:两种方案均安全有效。在完成28天随访的53例患者中,治愈率为100%。在两个治疗组之间,所有研究终点均具有可比性。结论:直肠青蒿琥酯10 mg / kg /天,3天,甲氟喹25 mg / kg的治疗方案最适合于单纯性恶性疟疾的治疗。将直肠青蒿琥酯的剂量从10毫克/千克/天增加到20美元/千克/天没有明显的益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号